Newly released documents reveal that Pfizer presented a study falsely claiming that its arthritis drug, Celebrex, was safer on the stomach than competing drugs, the New York Times reports.
U.S. regulators, retailers and manufacturers are growing increasingly concerned that a surge in the number of products being recalled is resulting in "fatigue" by the public — increasing the chance that consumers could ignore or miss a recall that could ultimately endanger their health, USA Today reports.
Anthony Coles, Onyx Pharmaceuticals president/CEO, discusses the status of his company's latest drugs.
If Americans ever eat genetically engineered fast-growing salmon, it might be because of a Soviet biologist turned oligarch turned government minister turned fish farming entrepreneur, the New York Times reports.
CNBC's Seema Mody reports on the latest details of the FDA advisory panel's review of Arena Pharmaceuticals' anti-obesity drug.
Ten days after the FDA sent warning letters to manufacturers of supplements with DMAA in it, the nation’s largest supplement retailers still have the product on the shelves.
In a wake of a warning letter sent to them by the FDA, some companies whose pre-workout or weight loss products include the ingredient DMAA, are starting to move on with life without it.
A warning letter written by the Food & Drug Administration last week to ten companies that produce pre-workout supplements with the ingredient dimethylamyamine (DMAA) has sent shockwaves through the industry, not only to the producers of the products but to consumers who have taken them.
CNBC's Darren Rovell reports on how shares of GNC Holdings and Vitamin Shoppe are holding up since Amazon.com announced they will be pulling products containing DMAA.
CNBC's Darren Rovell reports Amazon.com is pulling all products containing DMAA, an ingredient the FDA stated does not derive from a plant.
John Lechleiter, Eli Lilly chairman & CEO breaks down his company's earnings results of an adjusted $0.92 a share versus estimates of $0.78 est. and a look at the drug maker's generic challenges, and the politics of prescriptions.
U.S. securities regulators on Wednesday finalized long-awaited rules that will dictate which companies dealing in derivatives will be subject to costly capital, margin and business conduct requirements.
CNBC's Seema Mody reports on a major development in the early detection of Alzheimer's disease, and discussing how the FDA approved brain scan from Eli Lilly works, with Robert Petersen, M.D., Mayo Clinic.
Sharpen your pencils, it's Last Call quiz time.
A federal requirement would have begun forcing U.S. tobacco companies to put large graphic images on their cigarette packages, until a judge blocked the ruling Wednesday.
Vivus CEO Leland Wilson saw “a very powerful signal” that anti-obesity drug Qnexa would be approved.
Leland Wilson, Vivus CEO, discusses the optimist outlook for his company after an FDA panel backed its new diet drug, Qnexa; marketing strategies for the new product; and whether his company is now a potential takeover target, with the Fast Money traders.
Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.
There will be no silver bullet to reduce obesity, says Margaret Hamburg, FDA commissioner. Adding that, "generic drugs make a huge difference in patient care."
Generic drugs are in focus at Generic Pharmaceutical Association's annual meeting in Orlando, Florida. The hot button issue: backlog of generic drug applications at the Food & Drug Administration.